Cancer Stem Cell News Volume 9.34 | Sep 9 2020

    By
    Justin.choi
    -
    0
    315








    2020-09-09 | CSCN 9.34


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 9.34 – 9 September, 2020
    TOP STORY

    Chromatin
    Modifier MTA1 Regulates Mitotic Transition and Tumorigenesis by Orchestrating Mitotic mRNA Processing

    Researchers demonstrated that cancer metastasis-associated antigen 1 (MTA1), a well-known oncogenic chromatin modifier, broadly interacted and co-expressed with RNA binding proteins across cancers, contributing to cancerous mitosis-related alternative splicing.
    [Nature Communications]

    Full Article


    Long hours are a part of research. Maximize your efficiency.
    PUBLICATIONSRanked by the impact factor of the journal

    Transformable
    Dual‐Inhibition System Effectively Suppresses Renal Cancer Metastasis through Blocking Endothelial Cells and Cancer Stem Cells

    A transformable dual‐inhibition system based on a self‐assembly peptide was proposed to construct nanofibrous barriers on the cell membrane in situ, which reduced endothelial permeability and angiogenesis and inhibited stemness and metastasis of cancer stem cells in renal cancer.
    [Small]

    Abstract

    IL2RA
    Promotes Aggressiveness and Stem Cell-Related Properties of Acute Myeloid Leukemia

    The biological roles of interleukin-2 receptor alpha chain (IL2RA) were confirmed in two genetically distinct acute myeloid leukemia mouse models, this revealed that IL2RA inhibited differentiation, promoted stem cell-related properties, and was required for leukemogenesis.
    [Cancer Research]

    Abstract

    Differentiated
    Cancer Cell-Originated Lactate Promotes the Self-Renewal of Cancer Stem Cells in Patient-Derived Colorectal Cancer Organoids

    Organoid models were employed to show that cancer stem cells (CSCs) and non-CSCs in colorectal cancer were characterized by distinct metabolic phenotypes.
    [Cancer Letters]

    Abstract

    VDR–SOX2
    Signaling Promotes Colorectal Cancer Stemness and Malignancy in an Acidic Microenvironment

    Researchers revealed that acidosis reduced vitamin D receptor (VDR) expression by downregulating peroxisome proliferator-activated receptor delta expression. Overexpression of VDR effectively suppressed the stemness and oxaliplatin resistance of cells in acidosis.
    [Signal Transduction and Targeted Therapy]

    Full Article

    3D Co-Culture of Cancer-Associated Fibroblast with Oral Cancer Organoids

    The three-dimensional organoid model was employed to investigate whether co-culture with paralleled cancer-associated fibroblasts promoted stem-like properties of oral squamous cell carcinoma.
    [Journal of Dental Research]

    Abstract

    An
    RNA-Binding Protein, Hu-Antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

    Investigators elucidated the role of hu-antigen R (HuR) played in pancreatic cancer cell epithelial to mesenchymal transition and developed a novel inhibitor specifically interrupting HuR-RNA binding.
    [Molecular Cancer therapeutics]

    Abstract

    Drug
    Vulnerabilities and Disease Prognosis Linked to the Stem Cell-Like Gene Expression Program Triggered by the RHO GTPase Activator VAV2 in Hyperplastic Keratinocytes and Head and Neck Cancer

    Scientists showed that the VAV2-regulated stem cell-like program harbored a number of cell cycle- and signaling-related kinases that were essential for the viability of undifferentiated keratinocytes and head and neck squamous cell carcinomapatient-derived cells endowed with high levels of VAV2 activity.
    [Cancers]

    Full ArticleGraphical Abstract

    RBPJ
    Contributes to the Malignancy of Glioblastoma and Induction of Proneural-Mesenchymal Transition via IL-6-STAT3 Pathway

    Researchers knocked down immunoglobulin kappa J region (RBPJ) expression in two glioblastoma (GBM) cell lines and four GBM stem‐like cell lines derived from surgical samples of GBM to investigate the effect on cell proliferation, invasion, stemness, and tumor formation ability.
    [Cancer Science]

    Abstract

    Identification
    and Validation of Stemness-Related lncRNA Prognostic Signature for Breast Cancer

    Researchers evaluated the prognostic value of breast cancer stem cells (BCSC)-related long coding RNAs (lncRNAs) and eventually obtained a prognostic risk model consisting of 12 BCSC-related lncRNAs.
    [Journal of Translational Medicine]

    Full Article


    Subscribe to Science News for free weekly science newsletters.
    REVIEWS

    Epigenetic
    Regulations of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway

    The authors summarize the crosstalk between aryl hydrocarbon receptor and cancer genetics, with particular emphasis on mechanisms relevant to cancer stem cells such as Wnt/β-catenin pathway, Notch pathway, NF-κB pathway, PTEN-PI3K/Akt pathway and drug resistance-mediating pathways.
    [Seminars in Cancer Biology]

    Abstract

    Epitranscriptomics
    and Epiproteomics in Cancer Drug Resistance: Therapeutic Implications

    Investigators highlight the importance of epitranscriptomic and epiproteomic modification in cancer drug resistance and provide new insights on potential therapeutic targets to reverse cancer drug resistance.
    [Signal Transduction and Targeted Therapy]

    Full Article

    SATB2 Is a Novel Biomarker and Therapeutic Target for Cancer

    The authors discuss the pathophysiological roles of special AT-rich binding protein-2 (SATB2) and assess whether it could be used as a therapeutic target for cancer.
    [Journal of Cellular and Molecular Medicine]

    Full Article

    INDUSTRY AND POLICY NEWS

    Ascentage Pharma’s BC-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

    Ascentage Pharma announced that the FDA has granted APG-2575, an Orphan Drug Designation for the treatment of chronic lymphocytic leukemia.
    [Ascentage Pharma (PRNewswire, LLC)]

    Press Release

    PRA Health Sciences Joins The Leukemia & Lymphoma Society on Global Trial for Children with Acute Leukemia

    The Leukemia & Lymphoma Society and PRA Health Sciences announced a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia.
    [The Leukemia & Lymphoma Society (PRNewswire,LLC)]

    Press Release

    Brain
    Tumor Drug Receives Rare Disease Designations from the FDA

    The FDA awarded Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma and Orphan Drug Designation for treatment of malignant glioma to OKN-007.
    [Oklahoma Medical Research Foundation]

    Press Release

    FEATURED EVENT

    Allergy and Clinical Immunology Update 2020 – Save the Date!

    September 26
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Human Pluripotent Stem Cells, Hematopoiesis and Leukemia

    Icahn School of Medicine at Mount Sinai – New York City, New York, United States

    Postdoctoral Fellow – Immunology, Genetics, Precision Medicine

    St. Anna Children’s Cancer Research Institute – Vienna, Austria

    Postdoctoral Associate – RNA Epigenetics in Cancer Stem Cells

    Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States

    Faculty Position – Prostate Cancer Biology and Cancer Epigenetics

    Northwestern University – Chicago, Illinois, United States

    Postdoctoral Fellowship – Hematopoiesis, Leukemia, and Bone Marrow Failure Syndromes

    The University of Texas Southwestern Medical Center – Dallas, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cancer Stem Cell News
    Archives Contact Us
    Cancer Stem Cell News Twitter


    Brought to you by